Skip to main content

Table 1 Patient characteristics in the different data sources

From: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

 

Source of data

ABCS

BCAC

BOSOM

EMC

HEBON

NCR

Number of patients

2763

186,594

7105

3483

16,617

160,861

Eligibility criteria, number of patients excluded

      

 Studies from Asian countries

7146

 Patients of non-European descent

74

51,328

 Patients younger than 18 years old

4

 Year of PBC diagnosis before 1990

4014

3126

1132

 Year of PBC diagnosis missing

15,435

2

 PBC stage 0

123

38

2

 PBC stage IV

149

1811

104

115

7774

 Patients did not undergo surgery

24

1247

43

5

293

9278

Number of eligible patients

2393

105,571

3830

3478

15,075

143,809

No follow-up or follow-up less than 3 months

173

15,804

70

88

2382*

3396

Familiar breast cancer studies

6739

Studies with less than 10 CBC events

37,994

Number of patients included in the analysis (number of patients with CBC)

2220 (44)

45,034 (1001)

3760 (288)

3390 (221)

12,693 (918)

140,413 (5753)

Total number of patients included in the analysis (number of CBC)

207,510 (8225 of which 6828 invasive and 1397 in situ)

  1. ABCS: Amsterdam Breast Cancer Study, BCAC Breast Cancer Association Consortium, BOSOM Breast Cancer Outcome Study of Mutation carriers, EMC Erasmus Medical Center, HEBON Hereditary Breast and Ovarian cancer study Netherlands, NCR Netherlands Cancer Registry, PBC primary breast cancer, CBC contralateral breast cancer
  2. *1433 tested for BRCA1/2 germline mutation after CBC or preventive mastectomy
  3. BCAC is composed of 106 studies worldwide. The 45,034 patients selected for the analysis came from 18 studies